Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 4/20 | 0.39 |
| ▸ | IL1B | P01584 | 3/20 | 0.39 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22857769 | 0.83 | CRBN (0.46) | CRBNIKZF3DDB1HDAC3HDAC1 | |
| SCHEMBL21897792 | 0.83 | CRBN (0.46) | CRBNIKZF3DDB1ALDH1A1CHRM2 | |
| SCHEMBL20759933 | 0.83 | CRBN (0.45) | CRBNIKZF3DDB1ALDH1A1CHRM2 | |
| SCHEMBL24818018 | 0.82 | CRBN (0.48) | CRBNIKZF3DDB1HDAC3HDAC1 | |
| SCHEMBL19541974 | 0.82 | CRBN (0.49) | CRBNIKZF3DDB1HDAC3HDAC1 | |
| SCHEMBL22243534 | 0.82 | CRBN (0.56) | CRBNIKZF3DDB1HDAC3HDAC1 | |
| SCHEMBL20760681 | 0.81 | ATM (0.44) | CRBNIKZF3DDB1ALDH1A1CHRM2 | |
| SCHEMBL21982837 | 0.80 | ADRA2A (0.40) | CRBNDDB1 | |
| SCHEMBL24654316 | 0.80 | ADRA2A (0.40) | CRBNDDB1 | |
| SCHEMBL24812182 | 0.79 | CRBN (0.46) | CRBNIKZF3DDB1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | CRBN 5/4885IKZF3 1222/4885DDB1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.